Veracyte, Inc. (VCYT)
After hours:
| Previous Close | 19.20 |
| Open | 19.11 |
| Bid | 19.39 x 200 |
| Ask | 19.48 x 200 |
| Day's Range | 19.02 - 19.52 |
| 52 Week Range | 18.61 - 30.52 |
| Volume | |
| Avg. Volume | 647,585 |
| Market Cap | 1.46B |
| Beta (5Y Monthly) | 1.64 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.02 |
| Earnings Date | May 02, 2024 - May 06, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 30.83 |
Business WireVeracyte Announces that Nine Studies Reinforcing the Value of Decipher Prostate and Decipher Bladder Testing Will Be Presented at AUA 2024
SOUTH SAN FRANCISCO, Calif., April 16, 2024--Veracyte Announces that Nine Studies Reinforcing the Value of Decipher Prostate and Decipher Bladder Testing Will Be Presented at AUA 2024
Insider MonkeyWhat Makes Veracyte (VCYT) a Lucrative Investment?
Next Century Growth Investors, LLC, an investment Management Company, released its “Micro-Cap Strategy” fourth-quarter investor letter. A copy of the letter can be downloaded here. The recent surge in the stock market highlights the significance of current macroeconomic indicators and the Fed’s outlook on future interest rates. The strategy returned 9.54% (net of fees) compared to […]
Business WireVeracyte’s Decipher Prostate Test Receives Highest Evidence-Level Rating Among Molecular Tests in Updated Prostate Cancer NCCN Guidelines
SOUTH SAN FRANCISCO, Calif., February 27, 2024--Veracyte’s Decipher Prostate Test Receives Highest Evidence-Level Rating Among Molecular Tests in Updated Prostate Cancer NCCN Guidelines.
